Key terms
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TVTX news
Mar 27
9:24am ET
Travere downgraded to Neutral at Guggenheim on smaller role in IgAN space
Mar 27
6:43am ET
Travere Therapeutics downgraded to Neutral from Buy at Guggenheim
Mar 13
9:55am ET
Buy Rating Affirmed for Travere Therapeutics on Strong FILSPARI Data and Favorable Regulatory Outlook
Mar 11
7:42am ET
Travere Therapeutics submits sNDA for FILSPARI for IgAN
Feb 27
11:50pm ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Moderna (MRNA) and Travere Therapeutics (TVTX)
Feb 24
9:59am ET
Travere’s Sparsentan Nears European Market Breakthrough
Feb 23
10:35am ET
Buy Rating Affirmed: Expanding Market Potential for Travere Therapeutics’ Sparsentan
Feb 23
10:23am ET
Travere Therapeutics price target lowered to $17 from $20 at H.C. Wainwright
Feb 23
7:09am ET
Travere , CSL Vifor announce Sparsentan received positive CHMP opinion
Feb 23
5:14am ET
Travere Therapeutics, CSL Vifor get CHMP recommendation for sparsentan approval
Feb 21
1:01am ET
New Debt & Financing Risk for Travere Therapeutics, Inc. – What’s the Latest?
Feb 18
11:47pm ET
Buy Rating Affirmed for Travere Therapeutics Amidst Strong Filspari Launch and Promising Growth Prospects
Feb 16
5:40pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Travere Therapeutics (TVTX) and 10x Genomics (TXG)
Feb 16
5:23pm ET
Travere Therapeutics price target raised to $14 from $10 at Citi
Feb 16
8:39am ET
Wedbush Sticks to Their Buy Rating for Travere Therapeutics (TVTX)
Feb 16
7:38am ET
Piper Sandler Gives a Hold Rating to Travere Therapeutics (TVTX)
Feb 16
6:58am ET
Travere Therapeutics (TVTX) Gets a Buy from Barclays
Feb 16
5:47am ET
Travere Therapeutics: Hold Rating Amidst Filspari’s Steady Performance and Emerging Market Competition
Feb 16
5:09am ET
Bank of America Analyst Reaffirms Buy Rating on Travere Therapeutics Citing Strong Sales and Growth Potential
Feb 15
8:40pm ET
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Travere Therapeutics (TVTX) and Grifols SA (GRFS)
Feb 15
4:12pm ET
Travere Therapeutics reports Q4 EPS (94c), consensus ($1.22)
Jan 29
11:45am ET
Strategic Partnerships and Regulatory Advancements Anchor Buy Rating for Travere Therapeutics
Jan 26
3:11am ET
Analysts Are Bullish on These Healthcare Stocks: Abbott Labs (ABT), Travere Therapeutics (TVTX)
Jan 25
4:25pm ET
Travere in $120M licensing deal with Renalys to develop sparsentan in Asia
Jan 25
7:37am ET
Travere Therapeutics price target raised to $15 from $12 at TD Cowen
Jan 25
6:50am ET
Analysts Are Bullish on These Healthcare Stocks: BeiGene (BGNE), Travere Therapeutics (TVTX)
Jan 18
7:35am ET
Travere Therapeutics price target raised to $11 from $10 at Piper Sandler
Jan 11
1:27am ET
Travere Therapeutics: A Strong Buy on Filspari’s Outperformance and Promising Market Prospects
Jan 09
6:38am ET
Bullish Outlook: Buy Rating on Travere Therapeutics Amidst Strong FILSPARI Sales and Promising Milestones
Jan 08
7:41am ET
Travere Therapeutics announces anticipated 2024 milestones
Jan 08
7:38am ET
Travere Therapeutics sees 2023 net product sales from cont. ops. $40M
No recent press releases are available for TVTX
TVTX Financials
Key terms
Ad Feedback
TVTX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TVTX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
